. But there's little agreement on how to finance their development, and the situation is deteriorating.Antibiotics are a bad business, at least based on a current pharma model that's predicated on volume sales.
That's driven most incumbents out of the business, bankrupted some pure play developers, and scared off many venture capitalists. But today it did announce a new deal: Plugging around $9 million into BioVersys, a Swiss company in the clinic with a product aimed at certain lung and bloodstream infections that kill up to 100,000 people per year. It also has early-stage programs, including one aimed at multidrug-resistant tuberculosis.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: